DNA-repair defects in pancreatic neuroendocrine tumors and potential clinical applications

Cancer Treatment Reviews

Volumn 44, Issue , 2016, Pages 1-9

  Liu, Iris H ^a   Ford, James M ^b   Kunz, Pamela L ^b  

^a DARTMOUTH COLLEGE   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Carcinoid; DNA repair; MGMT; MMR; Neuroendocrine tumor

Indexed keywords

METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; MISMATCH REPAIR PROTEIN PMS2; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN MLH1; PROTEIN MSH2; PROTEIN MSH6; DNA LIGASE; DNA METHYLTRANSFERASE; MEN1 PROTEIN, HUMAN; MGMT PROTEIN, HUMAN; ONCOPROTEIN; PTEN PROTEIN, HUMAN; TUMOR SUPPRESSOR PROTEIN;

CANCER PROGNOSIS; CARCINOGENESIS; DISORDERS OF DNA SYNTHESIS AND REPAIR; DNA END JOINING REPAIR; DNA METHYLATION; DNA REPAIR; DOUBLE STRANDED DNA BREAK; EXCISION REPAIR; GENE; GENE EXPRESSION; GENE FUNCTION; GENE MUTATION; HOMOLOGOUS RECOMBINATION; HUMAN; MEN1 GENE; MGMT GENE; MISMATCH REPAIR; PANCREATIC NEUROENDOCRINE TUMOR; PREDICTIVE VALUE; PROMOTER REGION; PROTEIN EXPRESSION; PTEN GENE; REVIEW; GENETICS; NEUROENDOCRINE TUMOR; PANCREAS TUMOR;

DNA METHYLATION; DNA MISMATCH REPAIR; DNA MODIFICATION METHYLASES; DNA REPAIR; DNA REPAIR ENZYMES; HUMANS; NEUROENDOCRINE TUMORS; PANCREATIC NEOPLASMS; PROMOTER REGIONS, GENETIC; PROTO-ONCOGENE PROTEINS; PTEN PHOSPHOHYDROLASE; TUMOR SUPPRESSOR PROTEINS;

EID: 84975764643     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2015.11.006     Document Type: Review

References (100)

1. Oberg K., Castellano D. Current knowledge on diagnosis and staging of neuroendocrine tumors. Cancer Metastasis Rev 2011, 30(Suppl. 1):3-7.
2. Fesinmeyer M.D., Austin M.A., Li C.I., De Roos A.J., Bowen D.J. Differences in survival by histologic type of pancreatic cancer. Cancer Epidemiol Biomarkers Prev 2005, 14(7):1766-1773.
3. Yao J.C., Eisner M.P., Leary C., et al. Population-based study of islet cell carcinoma. Ann Surg Oncol 2007, 14(12):3492-3500.
4. Pape U.F., Berndt U., Muller-Nordhorn J., et al. Prognostic factors of long-term outcome in gastroenteropancreatic neuroendocrine tumours. Endocr Relat Cancer 2008, 15(4):1083-1097.
5. Ries LAG, Young J.L., Keel G.E., Eisner M.P., Lin Y.D., Horner M-J. SEER survival monograph: cancer survival among adults: U.S. SEER program, 1988-2011, patient and tumor characteristics 2007, National Cancer Institute, SEER Program.
6. Oberg K. Pancreatic endocrine tumors. Semin Oncol 2010, 37(6):594-618.
7. Li J., Yen C., Liaw D., et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 1997, 275(5308):1943-1947.
8. McEllin B., Camacho C.V., Mukherjee B., et al. PTEN loss compromises homologous recombination repair in astrocytes: implications for glioblastoma therapy with temozolomide or poly(ADP-ribose) polymerase inhibitors. Cancer Res 2010, 70(13):5457-5464.
9. Mendes-Pereira A.M., Martin S.A., Brough R., et al. Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors. EMBO Mol Med 2009, 1(6-7):315-322.
10. Tutt A., Robson M., Garber J.E., et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet 2010, 376(9737):235-244.
11. Knizhnik A.V., Roos W.P., Nikolova T., et al. Survival and death strategies in glioma cells: autophagy, senescence and apoptosis triggered by a single type of temozolomide-induced DNA damage. PLoS One 2013, 8(1):e55665.
12. Curtin N.J., Wang L.Z., Yiakouvaki A., et al. Novel poly(ADP-ribose) polymerase-1 inhibitor, AG14361, restores sensitivity to temozolomide in mismatch repair-deficient cells. Clin Cancer Res 2004, 10(3):881-889.
13. Raymond E., Dahan L., Raoul J.L., et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 2011, 364(6):501-513.
14. Thearle M.S., Freda P.U., Bruce J.N., Isaacson S.R., Lee Y., Fine R.L. Temozolomide (Temodar(R)) and capecitabine (Xeloda(R)) treatment of an aggressive corticotroph pituitary tumor. Pituitary 2011, 14(4):418-424.
15. Cartwright T.H., Cohn A., Varkey J.A., et al. Phase II study of oral capecitabine in patients with advanced or metastatic pancreatic cancer. J Clin Oncol 2002, 20(1):160-164.
16. Strosberg J.R., Fine R.L., Choi J., et al. First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas. Cancer 2011, 117(2):268-275.
17. Palma J.P., Rodriguez L.E., Bontcheva-Diaz V.D., et al. The PARP inhibitor, ABT-888 potentiates temozolomide: correlation with drug levels and reduction in PARP activity in vivo. Anticancer Res 2008, 28(5A):2625-2635.
18. 6-methylguanine-DNA methyltransferase activity. Mol Cancer Ther 2009, 8(8):2232-2242.
19. Isakoff S., Overmoyer B., Tung N., et al. P3-16-05: a phase II trial expansion cohort of the PARP inhibitor veliparib (ABT888) and temozolomide in BRCA1/2 associated metastatic breast cancer. Cancer Res 2012, 71(Suppl. 24). P3-16-05.
20. Meyers M., Hwang A., Wagner M.W., Boothman D.A. Role of DNA mismatch repair in apoptotic responses to therapeutic agents. Environ Mol Mutagen 2004, 44(4):249-264.
21. Kunkel T.A., Erie D.A. DNA mismatch repair. Annu Rev Biochem 2005, 74:681-710.
22. Lynch H.T., de la Chapelle A. Hereditary colorectal cancer. N Engl J Med 2003, 348(10):919-932.
23. Iyama T., Wilson D.M. DNA repair mechanisms in dividing and non-dividing cells. DNA Repair 2013, 12(8):620-636.
24. de Boer J., Hoeijmakers J.H. Nucleotide excision repair and human syndromes. Carcinogenesis 2000, 21(3):453-460.
25. Kraemer K.H., Patronas N.J., Schiffmann R., Brooks B.P., Tamura D., DiGiovanna J.J. Xeroderma pigmentosum, trichothiodystrophy and Cockayne syndrome: a complex genotype-phenotype relationship. Neuroscience 2007, 145(4):1388-1396.
26. Krokan H.E., Bjoras M. Base excision repair. Cold Spring Harbor Perspect Biol 2013, 5(4):a012583.
27. Robertson A.B., Klungland A., Rognes T., Leiros I. DNA repair in mammalian cells: base excision repair: the long and short of it. Cell Mol Life Sci CMLS 2009, 66(6):981-993.
28. Lyons D.M., O'Brien P.J. Human base excision repair creates a bias toward -1 frameshift mutations. J Biol Chem 2010, 285(33):25203-25212.
29. Hanssen-Bauer A., Solvang-Garten K., Sundheim O., et al. XRCC1 coordinates disparate responses and multiprotein repair complexes depending on the nature and context of the DNA damage. Environ Mol Mutagen 2011, 52(8):623-635.
30. Barazzuol L., Jena R., Burnet N.G., et al. Evaluation of poly (ADP-ribose) polymerase inhibitor ABT-888 combined with radiotherapy and temozolomide in glioblastoma. Radiat Oncol 2013, 8:65.
31. Bryant H.E., Schultz N., Thomas H.D., et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 2005, 434(7035):913-917.
32. Calabrese C.R., Almassy R., Barton S., et al. Anticancer chemosensitization and radiosensitization by the novel poly(ADP-ribose) polymerase-1 inhibitor AG14361. J Natl Cancer Inst 2004, 96(1):56-67.
33. Horton J.K., Stefanick D.F., Naron J.M., Kedar P.S., Wilson S.H. Poly(ADP-ribose) polymerase activity prevents signaling pathways for cell cycle arrest after DNA methylating agent exposure. J Biol Chem 2005, 280(16):15773-15785.
34. Miknyoczki S.J., Jones-Bolin S., Pritchard S., et al. Chemopotentiation of temozolomide, irinotecan, and cisplatin activity by CEP-6800, a poly(ADP-ribose) polymerase inhibitor. Mol Cancer Ther 2003, 2(4):371-382.
35. Tentori L., Leonetti C., Scarsella M., et al. Systemic administration of GPI 15427, a novel poly(ADP-ribose) polymerase-1 inhibitor, increases the antitumor activity of temozolomide against intracranial melanoma, glioma, lymphoma. Clin Cancer Res 2003, 9(14):5370-5379.
36. De Summa S., Pinto R., Pilato B., et al. Expression of base excision repair key factors and miR17 in familial and sporadic breast cancer. Cell Death Dis 2014, 5:e1076.
37. Kuno T., Matsubara N., Tsuda S., et al. Alterations of the base excision repair gene MUTYH in sporadic colorectal cancer. Oncol Rep 2012, 28(2):473-480.
38. Weissman L., Jo D.G., Sorensen M.M., et al. Defective DNA base excision repair in brain from individuals with Alzheimer's disease and amnestic mild cognitive impairment. Nucleic Acids Res 2007, 35(16):5545-5555.
39. Mao Z., Bozzella M., Seluanov A., Gorbunova V. DNA repair by nonhomologous end joining and homologous recombination during cell cycle in human cells. Cell Cycle 2008, 7(18):2902-2906.
40. Jazayeri A., Falck J., Lukas C., et al. ATM- and cell cycle-dependent regulation of ATR in response to DNA double-strand breaks. Nat Cell Biol 2006, 8(1):37-45.
41. Wyman C., Ristic D., Kanaar R. Homologous recombination-mediated double-strand break repair. DNA Repair 2004, 3(8-9):827-833.
42. Jensen R.B., Carreira A., Kowalczykowski S.C. Purified human BRCA2 stimulates RAD51-mediated recombination. Nature 2010, 467(7316):678-683.
43. Helleday T. Homologous recombination in cancer development, treatment and development of drug resistance. Carcinogenesis 2010, 31(6):955-960.
44. McKinnon P.J. DNA repair deficiency and neurological disease. Nat Rev Neurosci 2009, 10(2):100-112.
45. Moynahan M.E., Pierce A.J., Jasin M. BRCA2 is required for homology-directed repair of chromosomal breaks. Mol Cell 2001, 7(2):263-272.
46. Welcsh P.L., King M.C. BRCA1 and BRCA2 and the genetics of breast and ovarian cancer. Hum Mol Genet 2001, 10(7):705-713.
47. Pastwa E., Blasiak J. Non-homologous DNA end joining. Acta Biochim Pol 2003, 50(4):891-908.
48. Lieber M.R. The mechanism of human nonhomologous DNA end joining. J Biol Chem 2008, 283(1):1-5.
49. Mao Z., Bozzella M., Seluanov A., Gorbunova V. Comparison of nonhomologous end joining and homologous recombination in human cells. DNA Repair 2008, 7(10):1765-1771.
50. Buck D., Malivert L., de Chasseval R., et al. Cernunnos, a novel nonhomologous end-joining factor, is mutated in human immunodeficiency with microcephaly. Cell 2006, 124(2):287-299.
51. Kerzendorfer C., O'Driscoll M. Human DNA damage response and repair deficiency syndromes: linking genomic instability and cell cycle checkpoint proficiency. DNA Repair 2009, 8(9):1139-1152.
52. Truong L.N., Li Y., Shi L.Z., et al. Microhomology-mediated end joining and homologous recombination share the initial end resection step to repair DNA double-strand breaks in mammalian cells. Proc Natl Acad Sci USA 2013, 110(19):7720-7725.
53. Amatu A., Sartore-Bianchi A., Moutinho C., et al. Promoter CpG island hypermethylation of the DNA repair enzyme MGMT predicts clinical response to dacarbazine in a phase II study for metastatic colorectal cancer. Clin Cancer Res 2013, 19(8):2265-2272.
54. Hegi M.E., Diserens A.C., Gorlia T., et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005, 352(10):997-1003.
55. Jiang X., Reardon D.A., Desjardins A., et al. O(6)-methylguanine-DNA methyltransferase (MGMT) immunohistochemistry as a predictor of resistance to temozolomide in primary CNS lymphoma. J Neurooncol 2013, 114(1):135-140.
56. 6-methylguanine DNA methyltransferase deficiency and response to temozolomide-based therapy in patients with neuroendocrine tumors. Clin Cancer Res 2009, 15(1):338-345.
57. 6-methylguanine-DNA methyl transferase (MGMT) and p53 in breast cancer. Jpn J Clin Oncol 2005, 35(3):121-125.
58. 6-alkylguanine-DNA alkyltransferase: regulation and importance in response to alkylating carcinogenic and therapeutic agents. Cancer Res 1990, 50(19):6119-6129.
59. Wick W., Platten M., Weller M. New (alternative) temozolomide regimens for the treatment of glioma. Neuro-oncology 2009, 11(1):69-79.
60. 6-alkylguanine-DNA alkyltransferase correlates with potentiation of temozolomide and CCNU toxicity in human tumour cells. Br J Cancer 1993, 67(6):1299-1302.
61. 6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia. Cancer Res 1999, 59(4):793-797.
62. Herman J.G., Baylin S.B. Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 2003, 349(21):2042-2054.
63. Liu L., Gerson S.L. Targeted modulation of MGMT: clinical implications. Clin Cancer Res 2006, 12(2):328-331.
64. Gilbert J.A., Adhikari L.J., Lloyd R.V., Halfdanarson T.R., Muders M.H., Ames M.M. Molecular markers for novel therapeutic strategies in pancreatic endocrine tumors. Pancreas 2013, 42(3):411-421.
65. House M.G., Herman J.G., Guo M.Z., et al. Aberrant hypermethylation of tumor suppressor genes in pancreatic endocrine neoplasms. Ann Surg 2003, 238(3):423-431. [Discussion 431-422].
66. Chan A.O., Kim S.G., Bedeir A., Issa J.P., Hamilton S.R., Rashid A. CpG island methylation in carcinoid and pancreatic endocrine tumors. Oncogene 2003, 22(6):924-934.
67. Arnold C.N., Sosnowski A., Schmitt-Graff A., Arnold R., Blum H.E. Analysis of molecular pathways in sporadic neuroendocrine tumors of the gastro-entero-pancreatic system. Int J Cancer 2007, 120(10):2157-2164.
68. Grasbon-Frodl E.M., Kreth F.W., Ruiter M., et al. Intratumoral homogeneity of MGMT promoter hypermethylation as demonstrated in serial stereotactic specimens from anaplastic astrocytomas and glioblastomas. Int J Cancer 2007, 121(11):2458-2464.
69. 6-alkylguanine-DNA alkyltransferase in malignant glioma. Mol Cancer Ther 2006, 5(10):2531-2539.
70. 6-methylguanine-DNA methyltransferase status in glioma: relationship between immunohistochemistry and methylation analysis. Am J Surg Pathol 2008, 32(8):1220-1227.
71. Mei M., Deng D., Liu T.H., et al. Clinical implications of microsatellite instability and MLH1 gene inactivation in sporadic insulinomas. J Clin Endocrinol Metab 2009, 94(9):3448-3457.
72. House M.G., Herman J.G., Guo M.Z., et al. Prognostic value of hMLH1 methylation and microsatellite instability in pancreatic endocrine neoplasms. Surgery 2003, 134(6):902-908. [Discussion 909].
73. Arnason T., Sapp H.L., Rayson D., et al. Loss of expression of DNA mismatch repair proteins is rare in pancreatic and small intestinal neuroendocrine tumors. Arch Pathol Lab Med 2011, 135(12):1539-1544.
74. Karamurzin Y., Zeng Z., Stadler Z.K., et al. Unusual DNA mismatch repair-deficient tumors in Lynch syndrome: a report of new cases and review of the literature. Hum Pathol 2012, 43(10):1677-1687.
75. Ming M., He Y.Y. PTEN in DNA damage repair. Cancer Lett 2012, 319(2):125-129.
76. Planchon S.M., Waite K.A., Eng C. The nuclear affairs of PTEN. J Cell Sci 2008, 121(Pt 3):249-253.
77. Hollander M.C., Blumenthal G.M., Dennis P.A. PTEN loss in the continuum of common cancers, rare syndromes and mouse models. Nature Rev Cancer 2011, 11(4):289-301.
78. Liaw D., Marsh D.J., Li J., et al. Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome. Nat Genet 1997, 16(1):64-67.
79. Zhou X., Hampel H., Thiele H., et al. Association of germline mutation in the PTEN tumour suppressor gene and Proteus and Proteus-like syndromes. Lancet 2001, 358(9277):210-211.
80. Jiao Y., Shi C., Edil B.H., et al. DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science 2011, 331(6021):1199-1203.
81. Perren A., Komminoth P., Saremaslani P., et al. Mutation and expression analyses reveal differential subcellular compartmentalization of PTEN in endocrine pancreatic tumors compared to normal islet cells. Am J Pathol 2000, 157(4):1097-1103.
82. Missiaglia E., Dalai I., Barbi S., et al. Pancreatic endocrine tumors: expression profiling evidences a role for AKT-mTOR pathway. J Clin Oncol 2010, 28(2):245-255.
83. Han X., Ji Y., Zhao J., Xu X., Lou W. Expression of PTEN and mTOR in pancreatic neuroendocrine tumors. Tumour Biol 2013.
84. Yachida S., Vakiani E., White C.M., et al. Small cell and large cell neuroendocrine carcinomas of the pancreas are genetically similar and distinct from well-differentiated pancreatic neuroendocrine tumors. Am J Surg Pathol 2012, 36(2):173-184.
85. Yao J.C., Shah M.H., Ito T., et al. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 2011, 364(6):514-523.
86. Saal L.H., Johansson P., Holm K., et al. Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity. Proc Natl Acad Sci USA 2007, 104(18):7564-7569.
87. Duerr E.M., Rollbrocker B., Hayashi Y., et al. PTEN mutations in gliomas and glioneuronal tumors. Oncogene 1998, 16(17):2259-2264.
88. Jang K.S., Song Y.S., Jang S.H., et al. Clinicopathological significance of nuclear PTEN expression in colorectal adenocarcinoma. Histopathology 2010, 56(2):229-239.
89. Mina S., Bohn B.A., Simon R., et al. PTEN deletion is rare but often homogeneous in gastric cancer. J Clin Pathol 2012, 65(8):693-698.
90. Rychahou P.G., Kang J., Gulhati P., et al. Akt2 overexpression plays a critical role in the establishment of colorectal cancer metastasis. Proc Natl Acad Sci USA 2008, 105(51):20315-20320.
91. Salvesen H.B., Stefansson I., Kalvenes M.B., Das S., Akslen L.A. Loss of PTEN expression is associated with metastatic disease in patients with endometrial carcinoma. Cancer 2002, 94(8):2185-2191.
92. Hendy G.N., Kaji H., Canaff L. Cellular functions of menin. Adv Exp Med Biol 2009, 668:37-50.
93. Gallo A., Agnese S., Esposito I., Galgani M., Avvedimento V.E. Menin stimulates homology-directed DNA repair. FEBS Lett 2010, 584(22):4531-4536.
94. Kim H.S., Lee H.S., Nam K.H., Choi J., Kim W.H. P27 loss is associated with poor prognosis in gastroenteropancreatic neuroendocrine tumors. Cancer Res Treat 2014, 46(4):383-392.
95. Corbo V., Dalai I., Scardoni M., et al. MEN1 in pancreatic endocrine tumors: analysis of gene and protein status in 169 sporadic neoplasms reveals alterations in the vast majority of cases. Endocr Relat Cancer 2010, 17(3):771-783.
96. Gortz B., Roth J., Krahenmann A., et al. Mutations and allelic deletions of the MEN1 gene are associated with a subset of sporadic endocrine pancreatic and neuroendocrine tumors and not restricted to foregut neoplasms. Am J Pathol 1999, 154(2):429-436.
97. Fang M., Xia F., Mahalingam M., Virbasius C.M., Wajapeyee N., Green M.R. MEN1 is a melanoma tumor suppressor that preserves genomic integrity by stimulating transcription of genes that promote homologous recombination-directed DNA repair. Mol Cell Biol 2013, 33(13):2635-2647.
98. Carriere A., Cargnello M., Julien L.A., et al. Oncogenic MAPK signaling stimulates mTORC1 activity by promoting RSK-mediated raptor phosphorylation. Curr Biol 2008, 18(17):1269-1277.
99. Gallo A., Cuozzo C., Esposito I., et al. Menin uncouples Elk-1, JunD and c-Jun phosphorylation from MAP kinase activation. Oncogene 2002, 21(42):6434-6445.
100. Kidd M., Schimmack S., Lawrence B., Alaimo D., Modlin I.M. EGFR/TGFalpha and TGFbeta/CTGF signaling in neuroendocrine neoplasia: theoretical therapeutic targets. Neuroendocrinology 2013, 97(1):35-44.